TScan Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc. is a U.S.-based biotechnology company listed on the NASDAQ market in the United States. The company was created to pursue a more precise form of cancer immunotherapy through T cell receptor-engineered T cell, or TCR-T, therapies. Its operational headquarters are in Waltham, Massachusetts, a major biotech cluster in the Boston area. For investors, TScan is best viewed as a clinical-stage oncology platform company: it has meaningful scientific optionality, but it also carries the execution, funding, and regulatory risks typical of early- to mid-stage cell therapy developers. TScan’s core business is centered on a proprietary discovery platform that identifies naturally occurring T-cell receptors capable of recognizing tumor-associated antigens in the context of specific HLA types. That platform underpins a pipeline spanning both hematologic malignancies and solid tumors. In hematologic cancers, the company is advancing donor-derived, allogeneic TCR-T candidates designed to reduce residual disease and prevent relapse around hematopoietic cell transplantation. In solid tumors, TScan is building a broader ImmunoBank and a multiplex treatment concept under the T-Plex framework, aiming to administer up to three TCR-T product candidates simultaneously based on the patient’s tumor targets and HLA profile. A notable competitive feature is TScan’s internal GMP manufacturing capability in Waltham. In a field where manufacturing complexity can slow development and inflate costs, owning part of the production infrastructure is strategically important. It supports faster iteration across programs and may help the company scale clinical supply more efficiently than peers that rely entirely on external manufacturing partners. The company also emphasizes its non-viral engineering approach and the expansion of HLA coverage, both of which are intended to widen patient eligibility and strengthen the clinical relevance of its pipeline. From a market-position standpoint, TScan operates in a highly competitive segment of cell therapy and oncology, where differentiation depends on clinical data, translational biology, and manufacturability. The company is still pre-commercial and therefore not yet supported by product sales; its near-term value drivers are clinical milestones, regulatory filings, and cash runway. In its most recent public updates in 2025 and early 2026, TScan highlighted strategic prioritization of its heme program, FDA clearance of IND applications for TSC-102-A01 and TSC-102-A03, and updated clinical data presentations. The company also stated that its cash resources are expected to fund operations into the second half of 2027, which is an important benchmark for a development-stage biotech. Overall, TScan combines a differentiated science platform with substantial binary-event exposure, making it a high-risk, high-upside name for public equity investors.